Extending these findings to the skin microenvironment, topical application of the Hsp90 inhibitor 17AAG significantly ameliorated disease severity in both passive transfer and active immunization mouse models of EBA. This evidence concerns the gene HSP90AA1 and acquired epidermolysis bullosa.